1. Home
  2. ICCM vs FEMY Comparison

ICCM vs FEMY Comparison

Compare ICCM & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IceCure Medical Ltd.

ICCM

IceCure Medical Ltd.

HOLD

Current Price

$0.68

Market Cap

45.5M

Sector

N/A

ML Signal

HOLD

Logo Femasys Inc.

FEMY

Femasys Inc.

HOLD

Current Price

$0.81

Market Cap

51.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICCM
FEMY
Founded
2006
2004
Country
Israel
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.5M
51.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
ICCM
FEMY
Price
$0.68
$0.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$2.50
$6.83
AVG Volume (30 Days)
403.0K
3.8M
Earning Date
11-19-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,975,000.00
$2,061,502.00
Revenue This Year
$13.67
$64.02
Revenue Next Year
$38.55
$147.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
63.53
52 Week Low
$0.59
$0.31
52 Week High
$1.66
$1.80

Technical Indicators

Market Signals
Indicator
ICCM
FEMY
Relative Strength Index (RSI) 40.13 47.72
Support Level $0.67 $0.83
Resistance Level $0.73 $0.96
Average True Range (ATR) 0.04 0.08
MACD 0.01 -0.02
Stochastic Oscillator 56.00 32.25

Price Performance

Historical Comparison
ICCM
FEMY

About ICCM IceCure Medical Ltd.

Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: